Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)

Between 2005 and 2008, we conducted separate phase II clinical testing of 3 distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n=13) or 1 of 2 receptor tyrosine kinase inhibitors (A...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shanafelt, Tait, Zent, Clive, Byrd, John, Erlichman, Charles, LaPlant, Betsy, Ghosh, Asish, Call, Timothy, Villalona-Calero, Miguel, Jelinek, Diane, Bowen, Deborah, Laumann, Kristina, Wu, Wenting, Hanson, Curtis, Kay, Neil
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3928074/
https://ncbi.nlm.nih.gov/pubmed/21054149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.524327
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires